Blood cancer research in 2015

12 Nov 2015

The financial year ends with a record annual investment of over £33 million in research – and we know what we need to do next in order to save more lives.

2015 – the year that we become Bloodwise – sees us make a record annual investment of over £33 million in research. Spanning from projects to understand the biology of blood cancers in the lab through to the development of new treatments, all of our work is focused on saving and improving the lives of patients and preventing blood cancers from happening in the first place.

We also complete a two year programme of research into the needs of patients, which will help us make wise decisions about how we invest the money our supporters raise.

One of the most significant findings from this research is that just five conditions account for nearly 70% of the lives lost to blood cancer within five years of diagnosis. These conditions are: myeloma, diffuse large B-cell lymphoma, acute myeloid leukaemia, myelodysplastic syndromes, and chronic lymphocytic leukaemia.

So this year, large parts of our research will focus on tackling these five conditions – and the things we learn will help us improve treatment for many other types of blood cancer too.

Together, we’ve changed the world for people with leukaemia, lymphoma, myeloma and other blood disorders since 1960 – but we won’t stop until every single person with blood cancer survives and can live their life to the full.